HOUSTON, Sept. 10, 2020 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary aesthetic platform technology,
today announced it has entered into a distribution and sales
agreement with Aesthetic Solutions, Inc. to distribute its Rapid
Acoustic Pulse (RAP) device and advanced design cartridges during
the initial U.S. commercial launch, targeted for the first half of
2021.
The team at Aesthetic Solutions, Inc. will strategically focus
on and target placement of the RAP device in physician practices
that currently treat high volumes of patients for tattoo removal
and cellulite reduction, upon FDA clearance. Their team will sell
and service the RAP devices until Soliton's direct sales force is
fully established for the expected national rollout.
As previously announced under Soliton's COVID-19 Adjusted
Commercialization Strategy, the RAP device is planned to
incorporate both the tattoo removal indication and the cellulite
reduction indication, pending FDA clearance of the cellulite
indication.
Join our more than 200K
subscribers here to follow the
Company: https://soly-investors.com
"We are excited to have set in place a plan for the strategic
distribution of our RAP device for our initial commercial launch,"
commented Christopher Capelli, MD,
founder, President and CEO of Soliton. "Aesthetic Solutions has an
exceptional reputation in the industry and we believe will generate
positive results for Soliton among dermatologists, particularly key
opinion leaders with strong relationships with their patients. Our
relationship with Aesthetic Solutions represents a key step forward
in accomplishing a successful commercial launch and we welcome
their team as our sales and distribution partner."
"We are thrilled to partner with Soliton for the sales and
distribution of its unique multi-indication aesthetic device," said
Tim Howder, President of Aesthetic
Solutions, Inc. "With 30 years of experience in aesthetic medical
device rentals and distribution, we are excited to apply our unique
skill sets in a program of strategic device distribution and
service. Our highly trained sales and service staff teams are eager
and ready to partner with Soliton to ensure success in the launch
of this exciting multi-use device. We are well-equipped to support
the company's upcoming launch and we look forward to a successful
relationship."
Soliton's RAP technology has not yet been cleared by the FDA for
cellulite reduction and is not available for sale in the United States for this indication.
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from The University of Texas on behalf of MD Anderson Cancer
Center. The Company's first FDA cleared commercial product will use
rapid pulses of acoustic shockwaves as an accessory to lasers for
the removal of unwanted tattoos. The Company is based in
Houston, Texas, and is actively
engaged in bringing the Rapid Acoustic Pulse ("RAP") device to the
market. The Company believes this "Soliton" method has the
potential to lower tattoo removal costs for patients, while
increasing profitability to practitioners, compared to current
laser removal methods. Soliton has completed a clinical study
using the RAP device to improve the appearance of cellulite and is
investigating potential additional capabilities of the RAP
technology. The device is currently cleared in the United States only for use in tattoo
removal and is not yet cleared for use to address cellulite.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995, which statements involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, our ability to successfully
launch our product. These statements relate to future events,
future expectations, plans and prospects. Although Soliton believes
that the expectations reflected in such forward-looking statements
are reasonable as of the date made, actual results or outcomes may
prove to be materially different from the expectations expressed or
implied by such forward-looking statements. Soliton has attempted
to identify forward-looking statements by terminology including
''believes,'' ''estimates,'' ''anticipates,'' ''expects,''
''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' "would," ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
in our filings with the Securities and Exchange Commission ("SEC"),
including under the heading " Risk Factors" in the Form 10-K for
year ended December 31, 2019 filed
with the SEC and as updated in our Form 10-Q filings and in our
other filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. Soliton
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-enters-into-distribution-agreement-with-aesthetic-solutions-inc-for-initial-commercial-launch-of-its-rap-device-301127276.html
SOURCE Soliton, Inc.